Company:  TRANSENTERIX INC. (TRXC)
Form Type:  10-K
Filing Date:  4/1/2013 
CIK:  0000876378 
Address:  635 DAVIS DRIVE
SUITE 300
 
City, State, Zip:  MORRISVILLE, North Carolina 27560 
Telephone:  919-765-8400 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.64  
Change: 
-0.15 (-5.38%)  
Trade Time: 
Jan 22  
Market Cap: 
$570.56M
Trade TRXC now with 

© 2019  
Description of Business
TransEnterix is a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery by addressing the clinical and economic challenges associated with current laparoscopic and robotic options in today's value-based healthcare environment. The Company is focused on the commercialization of the Senhance(TM) Surgical System, which digitizes laparoscopic minimally invasive surgery. The system allows for robotic precision, haptic feedback, surgeon camera control via eye sensing and improved ergonomics while offering responsible economics. The Senhance System has been granted a CE Mark in Europe for laparoscopic abdominal and pelvic surgery, as well as limited thoracic operations excluding cardiac and vascular surgery. In April 2017, the Company submitted a 510(k) application to the FDA for the Senhance System.
Register and access this filing in:     
  FORM 10-K
    PART I
      Item 1. Business.
      Item 1A. Risk Factors.
      Item 2. Properties.
      Item 3. Legal Proceedings.
      Item 4. Mine Safety Disclosures.
    PART II
      Item 5. Market for Registrant's Common Equity, Related ...
      Item 6. Selected Financial Data.
      Item 7. Management's Discussion and Analysis of Financial ...
        Results of Operations
        Liquidity and Capital Resources
      Item 7A. Quantitative and Qualitative Disclosures About ...
      Item 8. Financial Statements and Supplementary Data.
        REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
        BALANCE SHEET
        INCOME STATEMENT
        STOCKHOLDERS EQUITY
        CASH FLOW
        NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
          NOTE 14 - SUBSEQUENT EVENTS
      Item 9. Changes in and Disagreements with Accountants on ...
      Item 9A. Controls and Procedures.
      Item 9B. Other Information.
    PART III
      Item 10. Directors, Executive Officers and Corporate Governance.
      Item 11. Executive Compensation.
      Item 12. Security Ownership of Certain Beneficial Owners and ...
      Item 13. Certain Relationships and Related Transactions, and ...
      Item 14. Principal Accounting Fees and Services.
    PART IV
      Item 15. Exhibits, Financial Statement Schedules
    SIGNATURES
  EXHIBIT 21.1
    SUBSIDIARIES
  EXHIBIT 23.1
    CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
  EXHIBIT 31.1
    CERTIFICATIONS
  EXHIBIT 31.2
    CERTIFICATIONS
  EXHIBIT 32.1
    CERTIFICATION PURSUANT
  EXHIBIT 32.2
    CERTIFICATION PURSUANT